5:49 PM
 | 
Jul 26, 2010
 |  BC Extra  |  Company News

Panel asks NICE to reappraise Vidaza

A NICE appeals panel said the U.K. agency should reappraise Vidaza azacitidine from Celgene Corp. (NASDAQ:CELG) because its original appraisal against NHS use of the cancer drug only included one of two possible comparators. The...

Read the full 168 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >